FDA Approves Earlier Use of CAR-T Products for Myeloma

(MedPage Today) -- The FDA expanded the labels of two CAR T-cell products for multiple myeloma, allowing their use in earlier lines of treatment for relapsed or refractory disease. Ciltacabtagene autoleucel (cilta-cel; Carvykti) is now approved...
Source: MedPage Today Public Health - Category: American Health Source Type: news